This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.00% per year. These returns cover a period from January 1, 1988 through May 4, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Santa Clara, CA-based Agilent Technologies, Inc. was originally a spin-off from Hewlett-Packard. The company is an original equipment manufacturer (OEM) of a broad-based portfolio of test and measurement products serving multiple end markets. The company has three business segments, including Life Sciences & Applied Markets Group (LSAG), Diagnostics and Genomics Group (DGG) and Agilent Cross Lab Group (ACG). The company uses a direct sales model for the distribution of its products, which is supplemented by distributors, resellers, manufacturers’ representatives, telesales and electronic commerce.
Rally Continues to Start Thanksgiving Week
by Mark Vickery
Market participants look to be picking up where they left off last week.
Agilent to Report Q4 Earnings: What's in the Cards for the Stock?
by Zacks Equity Research
A's fourth-quarter performance is expected to have benefited from the growing ACG segment. However, falling end-market and regional sales raise concerns.
Stay Ahead of the Game With Agilent (A) Q4 Earnings: Wall Street's Insights on Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Agilent (A), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended October 2024.
Ametek (AME) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Ametek (AME) delivered earnings and revenue surprises of 2.47% and 0.89%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Cognex Corporation (CGNX) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Cognex (CGNX) delivered earnings and revenue surprises of 17.65% and 2.12%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Agilent Expands LSAG Segment: How Should You Approach the Stock?
by Zacks Equity Research
A's expanding LSAG portfolio may bode well for the stock, despite macroeconomic risks and stretched valuation.
Danaher to Benefit From Business Strength Amid Headwinds
by Zacks Equity Research
DHR stands to benefit from strength in the clinical diagnostics business, Abcam buyout and shareholder-friendly policies. Softness in the Instrument unit remains a concern.
Do Options Traders Know Something About Agilent Technologies (A) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Agilent Technologies (A) stock based on the movements in the options market lately.
Why Is Agilent (A) Up 1.2% Since Last Earnings Report?
by Zacks Equity Research
Agilent (A) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Agilent (A) Reliance on International Sales: What Investors Need to Know
by Zacks Equity Research
Evaluate Agilent's (A) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.